论文部分内容阅读
目的:探讨布地奈德/福莫特罗与沙美特罗/氟替卡松治疗中重度稳定期慢性阻塞性肺疾病的疗效差异。方法:收集2013年12月-2014年12月我院诊断为中重度稳定期慢性阻塞性肺疾病的100例患者作为本次研究对象,分为2组,50例研究组(接受布地奈德/福莫特罗治疗)和50例对照组(接受沙美特罗/氟替卡松治疗)。对比(1)研究组和对照组治疗前及治疗后肺功能情况、6分钟运动耐力指标。(2)研究组和对照组治疗疗效。结果:(1)研究组和对照组治疗前FEV1预计值、FEV1/FVC、6分钟运动耐力指标结果比较无差异(P>0.05);研究组和对照组治疗后FEV1预计值、FEV1/FVC、6分钟运动耐力指标结果比较有差异(P<0.05)。(2)研究组和对照组治疗有效率分别为92%、88%,结果比较无差异(P>0.05)。结论:本次研究认为布地奈德/福莫特罗与沙美特罗/氟替卡松治疗中重度稳定期慢性阻塞性肺疾病疗效相近,但前者对改善患者肺功能的效果更为肯定。
Objective: To investigate the efficacy of budesonide / formoterol and salmeterol / fluticasone in the treatment of moderate to severe chronic obstructive pulmonary disease. Methods: A total of 100 patients diagnosed as moderate-severe chronic obstructive pulmonary disease (COPD) from December 2013 to December 2014 in our hospital were enrolled in this study. The patients were divided into two groups. Fifty study groups (receive budesonide / Formoterol treatment) and 50 control group (salmeterol / fluticasone treatment). Comparison (1) The lung function of the study group and the control group before and after treatment, 6-minute exercise endurance index. (2) study group and control group curative effect. Results: (1) FEV1, FVC and 6-minute exercise tolerance index of study group and control group showed no significant difference before and after treatment (P> 0.05); FEV1, FEV1 / FVC, 6-minute exercise endurance index results were significantly different (P <0.05). (2) The treatment effective rates in the study group and the control group were 92% and 88% respectively, with no difference in the results (P> 0.05). CONCLUSIONS: This study concluded that budesonide / formoterol is similar in efficacy to salmeterol / fluticasone in the treatment of moderate-to-severe chronic obstructive pulmonary disease, but the former is more effective in improving lung function.